InforSense Expands Ongoing Collaboration with AstraZeneca
InforSense Ltd, the leader in integrative analytics platforms, today announced that AstraZeneca (NYSE, LSE, SSE: AZN) has strengthened their strategic commitment to InforSense technology across their research and development organization through a new multi-year global licensing deal. Scientists at AstraZeneca R&D sites will use InforSense’s workflow-based integrative analytics environment, InforSense® KDE, to derive research intelligence and enhance productivity in their core drug discovery programs. Financial terms of the agreement were not disclosed.
InforSense technology has been used at AstraZeneca since 2001. Following successful pilot installations, the global licensing agreement expands access to InforSense KDE across their R&D organization for integrative biology, chemistry and text mining applications. The agreement also includes professional services by InforSense to enable AstraZeneca to leverage their existing discovery software investments within InforSense KDE workflows.
“InforSense is delighted to expand our ongoing collaboration with AstraZeneca,” commented Joseph F. Donahue, Chief Business Officer of InforSense. “One of the major competitive discriminators between Pharma R&D pipelines will be the speed and effectiveness by which they integrate both external and internal data, as well as software tools, within and across domains. InforSense technology will enable AstraZeneca to provide such integration across their entire organization to leverage their knowledge of biology and chemistry research in new ways.”
“We have recognized the potential value of InforSense integrative analytics technology at AstraZeneca for effective research decision-making over recent years,” said Martyn Wilkins, Director of Discovery Informatics Portfolio at AstraZeneca. “By expanding our commitment to InforSense KDE, we will empower more scientists across our organization to effectively use information-driven analytics to inform and accelerate their research.”
About InforSense
InforSense Limited, the leader in integrative analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, financial services companies, and research institutes are using the company’s flagship product, InforSense KDE, to enhance productivity across life science R&D, healthcare, and business analytics. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.
About InforSense KDE
Using InforSense KDE, enterprises rapidly integrate and deliver virtually any data source, analytic software tool, service or application within a single informatics framework. Users link these components via visual workflows to dynamically answer any question using their data, however complex or transient. Organizations can also mine their analytical processes to discover and deploy expertise and best practices. InforSense KDE provides an open, extensible service-oriented architecture, built using industry standards including J2EE, XML, and WSDL. InforSense IOE is a state-of–the-art solution for enterprise-wide integrative analytics using Oracle’s advanced information management and processing capabilities. For further information on InforSense products and solutions, visit www.inforsense.com .
InforSense and the InforSense logo are registered trademarks of InforSense Limited. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information, please visit www.astrazeneca.com .
